. .
Closing Bell is Stockhead’s daily round-up of the biggest players in the ASX – the winners and losers alike.
On stocks with moving announcements, Biotech Immutep (ASX: IMM) held earnings higher after announcing results from a Phase IIb study program for its cancer-fighting Efti treatment.
10. December 2020 | Mike Cooper
10. December 2020 | Sam Jacobs
10. December 2020 | Sam Jacobs
Stockhead provides factual information when there is a reasonable likelihood of doubt.
The information is not intended to contain a recommendation or opinion on any financial product.
Stockhead’s morning newsletter makes it easy: market coverage, company profiles and industry insights from Australia’s top business journalists – all curated and delivered straight to your inbox every morning.
Market coverage, company profiles and industry insights from Australia’s top business journalists – all compiled and delivered straight to your inbox.
Immutep, ASX, ASX: IMM, stocks, metastatic breast cancer, NASDAQ: IMMP
World News – USA – Closing Bell: The Biggest Small Cap Movers Today at ASX – Stockhead
. . Related title :
– ASX share of the day: Immutep shares (ASX: IMM) rise 60% in study news
– Immutep Updates AIPAC Breast Cancer Study and Announces New Study
– Closing Bell: Today &’s largest small cap mover starts at the ASX
– Immutep& The Chinese partner starts a clinical phase II study for patients with metastatic breast cancer two studies in China »> Immutep& # 39; s (ASX: IMM) breast cancer therapy for phase two study in China tellt
– Immutep shares rise 57% higher thanks to two big announcements
– Immutep 72% after breast cancer study shows promising survival data
– Immutep&’s Chinese partner EOC Pharma starts phase II study on metastatic breast cancer
– Immutep reports statistically significant survival benefit for important patient groups in the ongoing phase IIb AIPAC study . . .
– Immutep – Overall Survival Data from AIPAC Breast Cancer Study of ph IIb
Ref: https://stockhead.com.au